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Trypanosoma cruzi is the causative agent of Chagas disease, a parasitic infection endemic in Latin America.
Currently there are no effective treatments for the chronic phase of the disease, when most patients are diagnosed,
therefore the development of new drugs is a priority area. Several triazoles, used as fungicides, exhibit trypa-
nocidal activity both in vitro and in vivo. The mechanism of action of such drugs, both in fungi and in T. cruzi, relies
in the inhibition of ergosterol biosynthesis affecting the cell viability and growth. Among them, terconazole was
the first triazole antifungal drug for human use. In this work, the trypanocidal activity of terconazole was eval-
uated using in vitro assays. In epimastigotes of two parasites strains from different discrete typing units (Y and
Dm28c) the calculated IC50 were 25.7 μM and 21.9 μM, respectively. In trypomastigotes and amastigotes (the
clinically relevant life-stages of T. cruzi) a higher drug susceptibility was observed with IC50 values of 4.6 μM and
5.9 μM, respectively. Finally, the molecular docking simulations suggest that terconazole inhibits the T. cruzi
cytochrome P450 14-α-demethylase, interacting in a similar way that other triazole drugs. Drug repurposing to
Chagas disease treatment is one of the recommended approach according to the criterion of international health
organizations for their application in neglected diseases.1. Introduction
Chagas disease is caused by infection with the protozoan parasite
Trypanosoma cruzi (Chagas, 1909). Although it has a broad geographic
distribution, it is an important cause of disability and mortality mainly in
Latin America with approximately 7 million infected, more than 70
million people at risk and about 14,000 deaths per year. Endemic Chagas
disease is strictly associated to poverty and socioeconomic development
and as a consequence of these factors only less than 1% of infected people
have access to diagnosis and current treatments (https://www.dndi.org/
diseases-projects/chagas/). Concerning the available drugs to treat
Chagas disease, the situation is also critical; at present there are only two
drugs available, benznidazole and nifurtimox, which were developed
more than 50 years ago. These drugs, in addition to present severe side
effects, are not efficient in the chronic phase of the disease when most
patients are diagnosed, highlighting the urgent need for the development
of new treatments (Perez-Molina and Molina, 2018).
In contrast to mammalian cells, trypanosomatids synthesize mostly
ergosterol instead of cholesterol, resembling the fungi sterol metabolism.).
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is an open access article under tIn fungal cells, disruption of ergosterol biosynthesis alters the membrane
structure and function producing an inhibition of cell growth. Azole-
based drugs have been used as antifungal agents since the 1980s
(Ghannoum and Rice, 1999). The mechanism of action of such com-
pounds is mediated by the inhibition of the cytochrome P450
14-α-demethylase (CYP51) which produces a critical decrease in ergos-
terol concentration. In T. cruzi azoles have been successfully tested as
trypanocidal compounds in the last decades (Buckner, 2008) demon-
strating that ergosterol biosynthesis pathway is an interesting target for
the development of new drugs for Chagas disease treatment. Recently,
many triazole derivatives, including posaconazole and ravuconazole
(Fig. 1) were tested in clinical trials for the treatment of chronic Chagas
disease (Urbina, 2009).
Terconazole, a synthetic triazole derivative structurally related to
fluconazole (Fig. 1), is an antifungal medication primarily used to treat
vaginal fungal infections which also acts inhibiting de novo sterol
biosynthesis through CYP51. In this work the trypanocidal activity of
terconazole was evaluated in different stages of the T. cruzi life cycle
using parasites from two discrete typing units (DTU) and the mechanism2019
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structure of triazole derivatives. Structures of four antifungal drugs with trypanocidal activity, including terconazole.
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2. Materials and methods
2.1. Parasites and cells
Epimastigotes (5  106 cells/mL) of the Y and Dm28c strains (DTU II
and I, respectively) were cultured at 28 C in plastic flasks (25 cm2),
containing 5 mL of BHT (brain-heart infusion-tryptose) medium sup-
plemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, 100 μg/
mL streptomycin and 20 μg/mL hemin. Vero cells (African green monkey
kidney) and L929 cells (murine fibroblasts) were cultured in MEM me-
dium supplemented with 10% heat inactivated FCS, 0.15% (w/v)
NaHCO3, 100 U/mL penicillin and 100 U/mL streptomycin at 37 C in
5% CO2. Trypomastigotes and amastigotes of the Y strain were obtained
from Vero infected cells as previously described (Andrews and Colli,
1982).2.2. Trypanocidal activity assays
T. cruzi epimastigotes (Y and Dm28c strains) were cultured as
described above, in 24-wells plate at a start density of 1 107 cells/mL in
BHT medium. Parasites were treated with different concentrations of
terconazole and the control drug benznidazole, and parasite proliferation
was determined after 48 h. The drugs were dissolved in dimethyl sulf-
oxide (DMSO). Trypanocidal activity in trypomastigotes and amastigotes2(Y strain) was performed using 1  106 cells/mL in 96-well plates and
incubating at 37 C for 24 h in the presence of the corresponding drug.
Growth was determined by counting in a Neubauer chamber or by
viability assays using “Cell Titer 96® Aqueous One Solution Cell Prolif-
eration Assay (MTS)” (Promega, Madison, WI, USA) according to the
manufacturer's instructions.
2.3. Cell viability assay
Cytotoxicity against L929 cells was determined by the crystal violet
staining assay. The cells (104 cells/well) were incubated in 96-well plates
with the corresponding concentrations of terconazole or DMSO only as
negative control and maintained at 37 ̊C in a 5% CO2 atmosphere for 24
h. At the end of treatment, cells were fixed for 15 min, and stained with
0.5 % crystal violet. After washing with water and drying, the absorbance
of stained cells was measured at 570 nm.
2.4. Docking simulations and structure analysis
The x-ray structure of T. cruzi sterol 14 α-demethylase cytochrome
P450 (CYP51) was obtained at the Protein Data Bank (https://www.rcsb.
org/; PDB ID: 2WX2) (Reigada et al., 2017) and the software AutoDock
4.2.6 (Morris et al., 2009) was employed for docking simulations. A grid
that includes the heme group that binds to the antifungal azoles such as
fluconazole, and the adjacent residues were used to calculate the optimal
energy conformations for the binding of terconazole to CYP51. The
C. Reigada et al. Heliyon 5 (2019) e01947program was run using a Lamarckian Genetic Algorithm 100 times, with
a population size of 300, and 2.7  104 as maximum number of
generations.
Shared chemical features between structures were identified by
feature-based structure alignments using the LigandScout algorithm
(Wolber and Langer, 2005).2.5. Statistics and data analysis
IC50 values were obtained by non-linear regression of dose-response
logistic functions, using GraphPad Prism 6.01 for Windows. All experi-
ments were performed in triplicate and the data are presented as mean 
standard deviation (SD).
3. Results
3.1. Effect of terconazole on epimastigotes
First, the effect of terconazole was evaluated on epimastigotes, the
insect stage of T. cruzi, of the Y strain (DTU II). Epimastigotes were
treated with the drug in concentrations between 0 and 100 μM and the
trypanocidal effect was determined 48 h post treatment. The calculated
IC50 (the concentration that kills 50% of the parasites) was 25.73 μM
(1.27). The reference drug, benznidazole, exhibited similar activity
against this strain with an IC50 of 22.01 μM (2.77). Considering that the
DTU I is the most relevant DTU, in terms of geographical distribution, in
South America, epimastigotes of the Dm28c strain were also tested.
Similar results were obtained for terconazole with an IC50 value of 21.94
μM (1.53), suggesting that terconazole is effective regardless of the
DTU (Fig. 2A). On the contrary, the calculated IC50 for benznidazole was
1.8-fold higher for Dm28c epimastigotes, with a value of 38.55 μM
(1.76).3.2. Effect of terconazole on trypomastigotes and amastigotes
Terconazole activity was also evaluated against the mammalian life-
stages of T. cruzi and the IC50 (concentration that decrease the viability
of parasites in a 50%) were calculated 24 h post treatment. The drug
presented trypanocidal activity against both parasitic forms, trypomas-
tigotes and amastigotes, with calculated IC50 values of 4.56 μM (0.32)
and 5.96 μM (0.35), respectively, as shown in Figs. 2B and 2C. Inter-
estingly, these results demonstrate that trypomastigotes and amastigotes
are 5.6 and 4.3-fold more susceptible to terconazole treatment than the
epimastigote stage, respectively. Moreover, terconazole was found to be
more effective than the control drug benznidazole against trypomasti-
gotes and amastigotes. The calculated IC50 values of benznidazole were
12.71 μM (1.53) for trypomastigotes and 11.4 μM (0.5) for
amastigotes.Fig. 2. Effect of terconazole on epimastigotes, trypomastigotes and amastigotes of T.
μM for 48 h (A) or 0–20 μM for 24 h (B and C). The concentrations required to inhibit
of the Y (red line) and Dm28c (blue line) strains (A), trypomastigotes (B) and amastigo
three independent experiments.
3The in vitro cytotoxic effect of terconazole was determined on
mammalian cells (L929 line) and the IC50 value was obtained to calculate
the selectivity index (SI) according to formula SI ¼ IC50 against L929
cells/IC50 against tripomastigotes. Cells exposed to the drug for 24 h in a
concentration range from 0 to 80 μM showed a SI of 5.1 (IC50 23.38μM 
3.76).3.3. Predicted mechanism of action of terconazole
In order to predict if terconazole has similar properties to those
experimentally determined for fluconazole, the common chemical reac-
tive groups and the binding parameters to the protein CYP51 were
calculated. To identify the common chemical features (groups that can
participate in chemical interactions with a macromolecule) between
terconazole and fluconazole the LigandScout algorithm was used.
Feature-based structure alignments were performed and the similarities
were calculated as the number of matched feature pairs (MFP; i.e. aro-
matic ring, hydrophobic area, hydrogen bond donor or acceptor, nega-
tive or positive ionizable atom and metal binding location). For these
comparisons the 14 features of fluconazole were set as references and
results showed that terconazole share all of them including 5 hydrogen
bond acceptors, 1 hydrogen bond donor, 3 aromatic rings, 4 hydrophobic
interactions and 1 positive ionizable group. Alignment results are sche-
matized in Fig. 3A.
Then, molecular docking simulations were performed in order to
predict the interactions between terconazole and CYP51. In the reported
x-ray structure of CYP51 from T. cruzi in complex with fluconazole (PDB
ID: 2WX2), the ligand binds in the active site by coordination to the heme
iron via the aromatic nitrogen atom of a triazole ring, by van der Waals
and aromatic interactions. In addition, twenty residues were located
within 7 A of fluconazole (Y103, I105, M106, F110, A115, Y116, L127,
L130, E205, L208, M284, A287, F290, A291, G292, H294, T295, L356,
M460, and V461) (Chen et al., 2010). According to the molecular
docking simulation, all of them, except I105 and E205 are in a similar
position within CYP51 at the same distance from terconazole (Fig. 3B).
4. Discussion
Azoles were extensively tested as trypanocidal agents (Lepesheva
et al., 2018). The first report for their use in T. cruzi included miconazole
and econazole (Docampo et al., 1981). Some years later it was reported
that ketoconazole has trypanocidal effect in a murine model of Chagas
disease (McCabe et al., 1983). It was found that itraconazole decreases
parasitemia to undetectable levels in murine models of T. cruzi infection
(McCabe et al., 1986). Most recently, the results of the trial CHAGASA-
ZOL, performed with chronic chagasic patients treated with pos-
aconazole, were partially unsatisfactory because of the high rates of
treatment failure (Molina et al., 2014). Additionally, the clinical trialcruzi. Parasites were treated with terconazole in concentrations between 0 - 100
50% of parasite growth or parasite survival were calculated using epimastigotes
tes (C) of the Y strain. The data is expressed as the mean  standard deviation of
Fig. 3. In silico predictions of the mechanism of action of terconazole. A) Reactive groups of terconazole and fluconazole. The LigandScout software was used to
identify the common chemical features between fluconazole and terconazole. AR, aromatic ring (purple circles); H, hydrophobic area (yellow remarks); PI, positive
ionizable atom (purple lines); HBA, hydrogen bond acceptor (red arrow); and HBD, hydrogen bond donor (green arrow). B) Molecular docking. Docking simulations
were performed using the software Autodock 4.2.6 and the x-ray structure of the T. cruzi CYP51 (PDB ID: 2WX2). Residues and the heme group (HEM, red) corre-
sponding to the fluconazole (green) and terconazole (light blue) binding sites in CYP51 are indicated.
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success rate (Torrico et al., 2018). However, other studies revealed that
the azole drugs called VNI, VFV and VT-1161 are highly efficient and
selective to eradicate T. cruzi in murine models of Chagas disease (Gue-
des-da-Silva et al., 2017; Hoekstra et al., 2016; Lepesheva et al., 2015;
Villalta et al., 2013). Similarly, two inhibitors of the last enzyme of the
ergosterol synthesis, Δ24(25) sterol methyl transferase (24-SMT), 22,
26-azasterol (AZA) and 24 (R,S),25-epiminolanosterol (EIL), inhibit the
proliferation of T. cruzi epimastigotes and amastigotes and these effects
are potentiated by CYP51 inhibitors. Synergic effects of AZA were also
observed in a murine model of acute Chagas disease (Urbina et al., 1996).
In addition, Braga et al. (2005) observed that other 24-SMT inhibitors
(WSP488,WSP501 andWSP561) have antiproliferative effects on T. cruzi
epimastigotes and induce marked ultrastructural changes in the cells.
Terconazole is an antifungal drug used to treat vaginal yeast infection,
available as creams or suppositories. Terconazole was first described in
the 1980s as a highly-active antifungal in dermatophytosis and candi-
diasis topical treatments and also possesses a moderate oral broad-
spectrum activity tested in guinea pigs, rats, mice and turkeys (Van
Cutsem et al., 1983). Here we demonstrate that terconazole has trypa-
nocidal activity in epimastigotes from different DTUs and also in the
clinically relevant life-stages of T. cruzi, trypomastigotes and amastigotes,
with IC50 values similar to those calculated for other azoles such as
posaconazole (IC50: 5.4 μM) (Botero et al., 2017). Furthermore, in this
study we show that terconazole is more potent against trypomastigotes
and amastigotes than the reference drug benznidazole not only according
to the IC50 values obtained in this work but also to those previously re-
ported by other authors (Moreno et al., 2010).
Related to the predicted mechanism of action, the molecular docking
simulations suggest that terconazole inhibits the sterol biosynthesis by
binding the T. cruzi cytochrome P450 14-α-demethylase in a very similar
way that other active azoles such as fluconazole.
These results are relevant since terconazole began to be used almost
40 years ago, but unlike other fungicides, its trypanocidal activity was
never studied in detail.
Because terconazole is used only as a vaginal cream (0.4% and 0.8%)
or suppositories, there are very few reports on its oral toxicity. According4to the DrugBank (https://www.drugbank.ca/) the oral lethal dose 50%
(LD50) values were found to be up to 1700 mg/kg in rat studies (https://
www.drugbank.ca/drugs/DB00251). This value is in accordance to that
reported for posaconazole, with a LD50 up to 2700 mg/kg in rats (Cer-
illiant®, Sigma-Aldrich safety data sheet). During the clinical trials, some
patients received posaconazole up to 1600 mg/day with similar adverse
effects than the lower doses (https://www.drugbank.ca/drugs/
DB01263). All these data allow us to suppose that, in case of being effi-
cient as a trypanocidal agent in infected mice, terconazole could be
administered orally for the treatment of Chagas disease.
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